Pharmaceuticals News and Research

RSS

Ebola research: an interview with Professor Easton, University of Warwick

Ebola virus belongs to a group of viruses that have been known for some time. It was first isolated as a result of an infection in a primate, in a monkey colony, in monkeys that were being used for research in the Philippines.

28 May 2014

Polyplus-transfection introduces FectoPRO transfection reagent

Polyplus-transfection SA, a privately-held company specializing in the development of innovative solutions for transfection, today announces the launch of FectoPRO, the latest optimised transfection reagent in their product portfolio. FectoPRO has been designed for high yields in medium and large-scale production of proteins and antibodies in mammalian cells.

28 May 2014

Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCRTM technology (MX ICE COLD-PCR).

28 May 2014

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.

28 May 2014

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a "use-as-required" testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).

28 May 2014

arGEN-X collaborates with Bayer Pharma for development of therapeutic antibodies

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X's SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies.

28 May 2014

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

28 May 2014

Pfizer drops AstraZeneca bid

Under United Kingdom takeover rules, Pfizer can submit another bid in six months, although it is unclear if it will do so or instead focus on growing its own business.

28 May 2014

Hospitals sue HHS over lengthy RAC appeals

The hospitals are demanding the agency fulfill its requirement to decide Medicare payment appeals within 90 days, instead of the current 16-month average.

28 May 2014

Case Western Reserve physician calls on FDA to address hidden risk of dangerous drugs side effects

The agency charged to protect patients from dangerous drug side effects needs to be far more vigilant when it comes to medications that affect blood pressure.

28 May 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Inovio Pharmaceuticals, Inc. announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge.

27 May 2014

Analytik announces UK and Ireland release of the SciAps Inspector 500 SWIR Raman for the pharmaceutical industry

Analytik, leading suppliers of innovative analytical instrumentation, announce the SciAps Inspector 500 SWIR Raman system for the pharmaceutical industry.

23 May 2014

Inovio Pharmaceuticals proposes 1-for-4 reverse split of common stock

Inovio Pharmaceuticals, Inc. today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock.

23 May 2014

New antibody appears to block sensations of pain, itching in mouse model

Duke University researchers have found an antibody that simultaneously blocks the sensations of pain and itching in studies with mice.

23 May 2014

International partnership of charities funds first immunotherapy clinical trial for children with neuroblastoma

Solving Kids' Cancer, the Neuroblastoma Children's Cancer Alliance (NCCA UK), and Joining Against Cancer in Kids (J-A-C-K) awarded its first grant through their INBRACED (International Neuroblastoma Research and Collaboration for Effective Delivery) initiative, which aims to improve access of promising clinical trials for children with high-risk neuroblastoma in North America, the UK and in Europe.

23 May 2014

NCCN receives $2M grant to evaluate effectiveness of volasertib in treatment of hematologic malignancies

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc.

23 May 2014

Acceleron, Celgene to give oral presentations on beta-thalassemia, myelodysplastic syndromes at EHA meeting

Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported that Acceleron, Celgene and investigators in the sotatercept and ACE-536 phase 2 clinical trials will give three oral presentations of interim data from ongoing studies in beta-thalassemia and myelodysplastic syndromes as well as a poster presentation of nonclinical data in sickle cell disease at the 19th Annual Congress of the European Hematology Association (EHA) in Milan, Italy from June 12-15, 2014.

22 May 2014

Agios Pharmaceuticals to present AG-221 Phase 1 study results at EHA meeting

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that new clinical data from the Phase 1 study of AG-221, an orally available, selective, potent inhibitor of the mutated IDH2 protein, will be highlighted in an oral presentation at the 19th Congress of the European Hematology Association (EHA) taking place June 12 -15, 2014 in Milan, Italy.

22 May 2014

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).

22 May 2014

Pharmaceuticals News and Research

Ebola research: an interview with Professor Easton, University of Warwick

Polyplus-transfection introduces FectoPRO transfection reagent

Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

Trimel announces top-line results of Phase II clinical trial evaluating efficacy of Tefina

arGEN-X collaborates with Bayer Pharma for development of therapeutic antibodies

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Pfizer drops AstraZeneca bid

Hospitals sue HHS over lengthy RAC appeals

Case Western Reserve physician calls on FDA to address hidden risk of dangerous drugs side effects

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

Inovio announces positive results on DNA-based monoclonal antibody therapy targeting CHIKV

Analytik announces UK and Ireland release of the SciAps Inspector 500 SWIR Raman for the pharmaceutical industry

Inovio Pharmaceuticals proposes 1-for-4 reverse split of common stock

New antibody appears to block sensations of pain, itching in mouse model

International partnership of charities funds first immunotherapy clinical trial for children with neuroblastoma

NCCN receives $2M grant to evaluate effectiveness of volasertib in treatment of hematologic malignancies

Acceleron, Celgene to give oral presentations on beta-thalassemia, myelodysplastic syndromes at EHA meeting

Agios Pharmaceuticals to present AG-221 Phase 1 study results at EHA meeting

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence